Department of Microbiology, University of Iowa, Iowa City, IA 52242, USA.
J Immunol. 2013 Apr 15;190(8):3854-8. doi: 10.4049/jimmunol.1202790. Epub 2013 Mar 6.
Memory CD8 T cells recognizing conserved proteins from influenza A virus (IAV), such as nucleoprotein, have the potential to provide protection in individuals who lack the proper neutralizing Abs. In this study, we show that the most potent CD8 T cell-inducing influenza vaccine on the market (Flumist) does not induce sufficient numbers of cross-reactive CD8 T cells to provide substantial protection against lethal nonhomologous IAV challenge. However, Flumist-primed CD8 T cells rapidly acquire memory characteristics and can respond to short-interval boosting to greatly enlarge the IAV-specific memory pool, which is sufficient to protect mice from nonhomologous IAV challenge. Thus, a current vaccine strategy, Flumist, may serve as a priming platform for the rapid induction of large numbers of memory CD8 T cells with the capacity for broad protection against influenza.
记忆 CD8 T 细胞识别流感病毒（IAV）的保守蛋白，如核蛋白，有可能为缺乏适当中和抗体的个体提供保护。在这项研究中，我们表明，市场上最有效的流感疫苗（Flumist）不能诱导足够数量的交叉反应性 CD8 T 细胞，以提供对致命性非同源 IAV 挑战的实质性保护。然而，Flumist 引发的 CD8 T 细胞迅速获得记忆特征，并能对短期加强免疫做出反应，从而大大扩大 IAV 特异性记忆池，足以保护小鼠免受非同源 IAV 挑战。因此，当前的疫苗策略 Flumist 可以作为一种启动平台，快速诱导大量具有广泛保护流感能力的记忆 CD8 T 细胞。
